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Abstract
The abnormalities of aortic valve morphology and function represent the most common cardiac-
valve lesion particularly in elderly. The etiology of aortic stenosis is degenerative-calcific in the
majority of patients. Many risk factors seems to be linked to the calcification and the stenosis of
the aortic valve but they must be confirmed. In this review the etiology and the possible
physiopathology of the aortic valve stenosis is discussed.
Review
The abnormalities of aortic valve morphology and func-
tion represent the most common cardiac-valve lesion,
with relevant implications both for medical and surgical
treatment. Particularly, the aortic valve sclerosis (aortic
valve thickening and calcification without pressure gradi-
ent) seem to affect about one fourth of adults over 65
years of age, while the aortic valve stenosis is present in 2–
9% of general population over 65 years of age; an
increased prevalence of both sclerosis and stenosis with
aging (48% and 4% in those over 85 years) is observed.
Furthermore, the number of the aortic valve procedures
performed over the last 10 years is increasing if we con-
sider the aortic valve replacement alone or combined with
myocardial revascularization; mitral valve surgery seems
to be constant in the same period. Also, the etiology of the
pathologic process of the aortic valve is changing in the
last years. Passik et al. analysed the valve characteristics in
646 patients with pure aortic stenosis who underwent
valve replacement between 1981 and 1985 at Mayo
Clinic. During the five years of the study, the relative fre-
quency of the postinflammatory disease (i.e. post-rheu-
matic) decreased from 30% to 18% and the relative
frequency of the bicuspid aortic valve changed from 37%
to 33%; in contrast, the relative frequency of degenerative-
calcific aortic stenosis (an "atherosclerotic" form of dis-
ease, see below) increased from 30% to 46%. These differ-
ences were striking in subjects older than 70 years [1].
Several studies have been published in the last years
which clarify the epidemiology of valvular disease and,
specifically, of aortic valve disease. In the The EuroHeart
Failure survey programme, a survey on the quality of care
among patients with heart failure in Europe, of 46.788
patients screened over a six-week period 11.327 (24%)
patients were enrolled with a suspected or confirmed
heart failure; a valve disease was the cause of heart failure
in 29% of the cases, compared with coronary artery dis-
ease in 68% and idiopathic dilated cardiomyopathy in 6%
[2]. In the Euro-Heart Survey of acute coronary syn-
dromes, 489 out of 10207 (4.8%) patients with acute cor-
onary syndromes enrolled had a significant valve disease.
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The more common abnormalities were ischemic mitral
regurgitation and calcific aortic stenosis. The patients with
valve disease were older, more likely females and with
comorbidities such as diabetes and chronic renal failure;
they more likely have had a prior CHF and LV dysfunc-
tion, cardiac ischemic event or revascularization. In-hos-
pital and 30-day mortality of the patients with valve
disease were significantly higher than those without
(13.4% and 15.5% versus 6.4% and 7.7%, respectively)
[3].
In the Euro Heart Survey on Valvular Heart Disease, aortic
valve stenosis was the most common valve abnormality
(33,9% and 46,6% in the overall group and surgical sub-
group, respectively). The etiology of aortic stenosis was
degenerative-calcific in the majority of patients (81,9%),
while it was rheumatic in 11.2%, congenital in 5.6% and
post-endocarditis in the remaining 1,3%. Among the 512
aortic stenosis patients who underwent valve replace-
ment, 54,3% were elderly (more than 70 years), 80% had
a preserved left ventricular systolic function (left ventricu-
lar ejection fraction >60%) and 85% had symptoms of
heart failure (NYHA class II-IV) [4].
Other studies evaluated the prevalence of calcific aortic
valve disease (sclerosis/stenosis) in the general popula-
tion. In the Helsinki Ageing Study, among 577 apparently
healthy subjects 75–86 years old some degree of aortic
valve calcification (independently from pressure gradient)
was observed in 53%; the prevalence of moderate to
severe aortic stenosis (Doppler valve area <1.2 cm2)
increased from 2.5% in the 75–76 years old group to 8.1%
in the 85–86 years old group [5].
In the Cardiovascular Health Study, the Doppler echocar-
diographic examination performed in 5621 subjects older
than 65 year without prevalent cardiovascular disease at
entry identified an aortic sclerosis (valve thickening and
iperreflectivity) in 29% of overall population and an aor-
tic stenosis (valve abnormalities and instantaneous pres-
sure gradient >25 mmHg) in 2% [6]. In hypertensive
patients of INSIGHT study [7], some degree of aortic valve
calcifications was present in 54% and in those of LIFE
echo substudy (960 hypertensive patients between 55 and
80 years old) the frequency of the aortic sclerosis was
40.4% and that of aortic stenosis 1.6% at the ultrasound
examination performed at admission; of particular inter-
est, after a follow up of 4 years, the frequency increased to
63% and 4%, respectively [8].
Aortic valve sclerosis is commonly defined as a focal or
diffuse thickening of the aortic cusps with calcific nodules
generally at the base of leaflets and transvalvular velocity
at Doppler still in the normal range (Vmax <2 m/s). Until
few years ago, it was considered a physiologic process
related to aging without clinical relevance. However, aor-
tic valve sclerosis is not observed in about 50% of people
over 80 years old. Furthermore, several experimental and
clinical studies have showed that it could represent an
active phenomenon, significantly related to risk factors for
atherosclerosis and cardiovascular morbidity and morbil-
ity [9]. In the previously mentioned Cardiovascular
Health Study, Stewart et Al. showed that clinical factors
associated with aortic valve sclerosis and stenosis are sim-
ilar to risk factors for atherosclerosis: age, male gender,
height (inverse relation), smoking, history of hyperten-
sion, elevated serum levels of Lipoprotein (a), and LDL-
cholesterol [6]. Furthermore, the rates of cardiovascular
events during follow-up were significantly higher in sub-
jects with compared to those without aortic valve sclero-
sis; the relative risk for cardiovascular mortality, acute
myocardial infarction and congestive heart failure was
66%, 46% and 33% higher, respectively in subjects with
aortic sclerosis. This excess of cardiovascular fatal and
nonfatal events could not be exclusively attributed to
complications, such as endocarditis and progression to
severe aortic stenosis, of the few cases of significant aortic
valve disease; thus, the hypothesis of an association
between valve sclerosis and atherosclerotic coronary
artery disease was formulated. In the Editorial comment
to this landmark paper, Carabello proposed the use of
aortic valve sclerosis as "a window to the coronary arteries?"
[10].
William C. Roberts, the eminent cardiac pathologist and
Editor in Chief of The American Journal of Cardiology,
twenty years ago used the term "senile cardiac calcifica-
tion syndrome" to indicate the simultaneous presence of
calcific deposits in epicardial coronary arteries, in the
mitral annular area, on the aortic valve cups and on the
head of left ventricular papillary muscles. Roberts stated
"... Thus, cardiac calcium is not good. It may narrow the
coronary arteries, mitral valve orifice and aortic valve ori-
fice and it may prevent either or both of these valvular ori-
fices from closing completely. It is reasonable to believe
that both mitral anular and aortic cuspal calcific deposits
in the elderly have the same etiology as the coronary
atherosclerotic plaques because the 3 are commonly
present in the same heart and the predisposing factors of
all 3 are the same." [11].
Subsequent studies confirmed this interesting idea: the
calcification of mitral annulus is associated with cardio-
vascular morbidity and mortality. In the Framingham
Heart Study, 1197 subjects with an adequate echocardio-
gram were followed for 16 years; 14% had the calcifica-
tion of mitral annulus. For each 1-mm increase in the
calcification of mitral annulus size, the risk of incident
cardiovascular diseases, cardiovascular mortality and totalCardiovascular Ultrasound 2006, 4:27 http://www.cardiovascularultrasound.com/content/4/1/27
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mortality, adjusted for relevant baseline risk factors,
increased by ≈10% [12], (Figure 1) [13].
The progressive nature of aortic valve calcification has also
been confirmed. Several studies documented the rate of
progression of severity of valve stenosis over time (Table
1) [14]; according to these reports an average reduction of
0.1 cm2 in valve area per year of follow-up is generally
observed; unfortunately, there is a large variability in the
rate of progression among patients. Furthermore, many
factors associated with a faster progression have been
identified. Of interest, among these there are hemody-
namic and valve-related variables, such as left ventricular
function, bicuspid type of stenosis, initial severity of sten-
osis, but also, and specially, risk factors for atherosclero-
sis, such as age, smoking, hypertension, obesity and
A – B – C – D Accordingly to the absence and presence cardiac calcifications identified, final score was calculated expressing  the sum of all: it was in the range from 0 (no calcium visible) to 8 (severe calcification of aortic valve and mitral annulus, pres- ence of calcium at the level of ascending aorta and papillary muscles) Figure 1
A – B – C – D Accordingly to the absence and presence cardiac calcifications identified, final score was calculated expressing 
the sum of all: it was in the range from 0 (no calcium visible) to 8 (severe calcification of aortic valve and mitral annulus, pres-
ence of calcium at the level of ascending aorta and papillary muscles). A – B No calcifications are visible at the level of aortic 
valve with a total calcium score of 0/8. C – D Calcifications are evident at multiple sites: mitral annulus, papillary muscles, aortic 
valve and ascending aortic wall with a total calcium score of 8/8.Cardiovascular Ultrasound 2006, 4:27 http://www.cardiovascularultrasound.com/content/4/1/27
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diabetes, lipid abnormalities, chronic renal failure and
dialysis, and atherosclerotic disease itself, such as con-
comitant coronary artery disease.
Patients on dialysis constitute a population at high risk for
cardiovascular events and valvular calcification. In a
group of patients on peritoneal dialysis the simultaneous
presence of vascular (arterial) and cardiac valve calcifica-
tions is associated with an increased cardiovascular mor-
tality risk of 73% compared to the absence of calcification
[15]. Aortic valve calcification is frequent in end-stage
renal failure and dialysis subjects ; among 155 hemodial-
ysis patients referred to our echo laboratory in the last 12
months, some degree of aortic valve sclerosis was found in
66,5%, aortic valve stenosis in 17,5% and only 16% of
subjects had a normal aortic valve (unpublished data).
Furthermore, rate of progression of aortic stenosis is par-
ticularly fast in these patients [unpublished data]. Again,
serum calcium-Phosphorus product, levels of Vitamin D
and the well known cardiovascular risk factors represent
favoring conditions.
Not only valve stenosis but even valve sclerosis is a pro-
gressive disease. Studies on rate of aortic valve sclerosis
progression have been published recently. Faggiano et al.
followed 400 subjects > 50 years old with aortic valve
thickening/calcification and peak vel ≤ 2 m/s (valve scle-
rosis without stenosis) During a follow-up period of 44 ±
30 months, 131 patients (32.7%) developed some degree
of aortic stenosis; furthermore, a pattern of rapid progres-
sion (rate of increase in peak aortic velocity 0.3 m/s/yr)
was observed in 24/400 patients (6%); among 100
patients with a longer follow-up (> 5 years) a mild aortic
stenosis appeared in 44%, a moderate in 14% and a severe
one in 8% [16].
In the LIFE study, the risk for developing aortic valve ste-
nosis was greater in patients with aortic valve sclerosis
compared with those with normal valve at baseline, after
1 year (2.8% versus 0.4%, p < 0.001) and after 4 years
(6.9% versus 0.9%, p < 0.001) of antihypertensive treat-
ment. Patients with abnormal compared to those with
normal aortic valves throughout the study had a greater
incidence of composite end points (16.8% versus 9.3%, p
0.05) confirming previous studies. The prevalence of aor-
tic valve sclerosis and mild aortic valve stenosis increased
continuously in this elderly, high-risk hypertensive popu-
lation, and this progression was prevented by neither losa-
rtan- nor atenolol-based treatment [8]. On the other
hand, Antonini-Canterin et Al. recently reported the
results of a retrospective study showing that long-term
therapy with lipid-lowering drugs, such as statin, was able
to slow the rate of progression of aortic valve sclerosis
[17].
Conclusion
Abnormalities of the aortic valve, without (aortic sclero-
sis) or with obstruction to left ventricular outflow (aortic
stenosis) are particularly frequent in the general popula-
tion, are associated to a high incidence of cardiovascular
events, are related to risk factors for atherosclerosis and
share similarities with atherosclerotic plaques (see other
sections of this supplements). The knowledge of pathoge-
netic mechanisms, rate of progression over time and
effects of medical treatment can guide our approach to
this common disease.
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Table 1: Findings associated to a faster progression of the aortic 
stenosis. The authors of the studies documented three 
subgroups of risk factors related to a faster progression: Patient-
related; Hemodynamic-related; Valve-related.
Patient-related
Older age
Smoking
Hypertension
Obesity/diabetes
Lipid abnormalities
Chronic renal failure
Symptoms appearance or worsening
Concomitant coronary artery disease
Hemodynamic-related
Left ventricular systolic dysfunction and/or low cardiac output
Hemodynamic changes during exercise
Dialysis
Valve-related
Bicuspid valve
Degenerative aortic stenosis
Valve calcification and regurgitation
Mild-moderate stenosis at initial presentationPublish with BioMed Central    and   every 
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